Point-of-care screening
AI devices that check for diabetic retinopathy at the point of care, or help primary care physicians decide whether to refer a skin lesion.
Category overviewHide category overview
LumineticsCore and EyeArt autonomously check retinal images for diabetic retinopathy, and DermaSensor gives primary care physicians a result on a skin lesion to inform referral. The American Medical Association's AI taxonomy cites retinal imaging, Current Procedural Terminology code 92229, as its example of autonomous AI, which generates clinically meaningful conclusions without concurrent physician involvement. Medicare set payment for the code at $45 to $64 per exam from Jan. 1, 2022, according to a 2022 paper. DermaSensor was the first AI-enabled skin cancer device FDA authorized for non-specialists, a commentary noted.
A 2024 meta-analysis of 34 studies on real-world images found pooled sensitivity of 94% and specificity of 89% for AI diabetic retinopathy screening, among gradable images. In a test of seven anonymized algorithms from five companies, sensitivities ranged from 50.98% to 85.90%, most did no better than human graders, and the authors called for real-world testing of every algorithm before clinical use. Open questions include ungradable images in routine care and unnecessary referrals from low specificity.
AEYE-DS
Autonomous AI that reads nonmydriatic retinal photographs for more-than-mild diabetic retinopathy, including from a handheld camera.
Read the full review with Pro
The grade is free. The evidence behind it, the prices and every source are for members.
Founding Pro: $149 a year, locked while you stay. Until Dec. 31. Regular price $249 a year.
Already a member? Sign in
DERM
AI that assesses dermoscopic images of suspicious skin lesions and recommends discharge or referral in NHS skin cancer pathways.
Caution. In an independent study of the first 1,230 lesions DERM assessed at an NHS trust in North West England, specificity in lesions with histopathology was 21% (dermatologists 61%), its suggested diagnosis matched histopathology in 28.6% of biopsied lesions, and four cancers were found among lesions it called benign that would have been discharged without human review. A 2026 health technology assessment pooled specificity of 65.4%.
DermaSensor
Handheld AI device for primary care that scans skin lesions with light to help decide on dermatology referral.
EyeArt
Autonomous AI that grades retinal photographs for more-than-mild and vision-threatening diabetic retinopathy.
LumineticsCore
Autonomous AI that checks retinal photographs taken at the point of care for more-than-mild diabetic retinopathy.
Caution. A report from a family medicine residency practice in Columbus, Ohio, whose authors reported no conflicts of interest, found 36% of exams were insufficient as of May 2023, when the practice began offering dilation to patients older than 64 or whose earlier undilated exams had failed, and 22% over the next eight months (Yun et al., Annals of Family Medicine, 2024); the pivotal trial reported imageability of 96.1%.
SkinVision
Consumer smartphone app that rates photographs of skin lesions as low or high risk for skin cancer.
Caution. In an independent prospective study of 1,904 lesions at Ghent University Hospital, image capture failed for 16.6% of lesions under optimal conditions and succeeded only 28.9% of the time in users' hands; sensitivity was 82.5%. An independent study at University Hospital Basel of 1,204 pigmented lesions found sensitivity of 41.3% to 83.3%, depending on the reference standard.
Reviews of the published evidence, not medical advice or an endorsement of any product.